Vascular Biogenics Ltd.

NasdaqCM:VBLT Stock Report

Market Cap: US$12.1m

Vascular Biogenics Balance Sheet Health

Financial Health criteria checks 6/6

Vascular Biogenics has a total shareholder equity of $19.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $24.6M and $5.4M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$24.26m
EquityUS$19.24m
Total liabilitiesUS$5.41m
Total assetsUS$24.65m

Recent financial health updates

Here's Why We're Watching Vascular Biogenics' (NASDAQ:VBLT) Cash Burn Situation

May 18
Here's Why We're Watching Vascular Biogenics' (NASDAQ:VBLT) Cash Burn Situation

Is Vascular Biogenics (NASDAQ:VBLT) In A Good Position To Deliver On Growth Plans?

Dec 24
Is Vascular Biogenics (NASDAQ:VBLT) In A Good Position To Deliver On Growth Plans?

Recent updates

VBL Therapeutics receives non-compliance letter from Nasdaq

Sep 01

VBL Therapeutics GAAP EPS of -$0.12

Aug 15

VBL Therapeutics' late-stage trial for ovarian cancer treatment does not meet main goals

Jul 19

Here's Why We're Watching Vascular Biogenics' (NASDAQ:VBLT) Cash Burn Situation

May 18
Here's Why We're Watching Vascular Biogenics' (NASDAQ:VBLT) Cash Burn Situation

Vascular Biogenics Trial Nears Full Enrollment, Price Could Jump

Sep 03

How Much Are Vascular Biogenics Ltd. (NASDAQ:VBLT) Insiders Spending On Buying Shares?

Mar 17
How Much Are Vascular Biogenics Ltd. (NASDAQ:VBLT) Insiders Spending On Buying Shares?

How Much Of Vascular Biogenics Ltd. (NASDAQ:VBLT) Do Insiders Own?

Jan 28
How Much Of Vascular Biogenics Ltd. (NASDAQ:VBLT) Do Insiders Own?

VBL Therapeutics expands the ovarian cancer trial in Europe

Dec 29

Is Vascular Biogenics (NASDAQ:VBLT) In A Good Position To Deliver On Growth Plans?

Dec 24
Is Vascular Biogenics (NASDAQ:VBLT) In A Good Position To Deliver On Growth Plans?

Vascular Biogenics Ltd. (NASDAQ:VBLT) Just Reported And Analysts Have Been Cutting Their Estimates

Nov 19
Vascular Biogenics Ltd. (NASDAQ:VBLT) Just Reported And Analysts Have Been Cutting Their Estimates

VBL Therapeutics EPS beats by $0.01, misses on revenue

Nov 16

Financial Position Analysis

Short Term Liabilities: VBLT's short term assets ($24.5M) exceed its short term liabilities ($5.3M).

Long Term Liabilities: VBLT's short term assets ($24.5M) exceed its long term liabilities ($108.0K).


Debt to Equity History and Analysis

Debt Level: VBLT is debt free.

Reducing Debt: VBLT had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VBLT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: VBLT has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 15.7% each year.


Discover healthy companies